Special article| Volume 114, ISSUE 4, P299-306, March 2003

Download started.


Troglitazone-induced liver failure: a case study



      Troglitazone was removed from the U.S. market because its use was associated with an increased risk of liver failure. We evaluated the clinical features of all cases reported to the Food and Drug Administration and estimated the duration and magnitude of the risk of liver failure associated with continued use of the drug.


      Data from cases of liver failure associated with troglitazone use were abstracted and analyzed. The extent of troglitazone use was determined from national marketing data, and the duration of use was estimated with data from a large, multistate, health care company. Survival analysis was performed to estimate monthly incidence rates and the cumulative risk of liver failure.


      Ninety-four cases of liver failure (89 acute, 5 chronic) were reported. Of the acute cases, 58 (67%) were women and only 11 (13%) recovered without liver transplantation. Progression from normal hepatic functioning to irreversible liver injury occurred within 1 month in 19 patients who were indistinguishable clinically from the 70 patients who had an unknown time course to irreversibility, except for the post hoc observation that prior cholecystectomy was less common in those with rapid onset. The incidence of liver failure was elevated from the first through at least the 26th month of troglitazone use. Accounting for case underreporting, the number needed to harm from troglitazone use was between 600 to 1500 patients at 26 months.


      The progression to irreversible liver injury probably occurred within a 1-month interval in most patients, casting doubt on the value of monthly monitoring of serum aminotransferase levels as a means of preventing troglitazone-induced acute liver failure. The cumulative risk of hepatic failure increased with continued use.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Imura H.
        A novel antidiabetic drug, troglitazone—reason for hope and concern.
        N Engl J Med. 1998; 338 ([editorial]): 908-909
        • Sigmund W.R.
        (Accessed October 10, 2001)
        • Sigmund W.R.
        (Accessed October 10, 2001)
        • Sigmund W.R.
        (Accessed October 10, 2001)
        • Sigmund W.R.
        (Accessed October 10, 2001)
        • Gitlin N.
        • Julie N.L.
        • Spurr C.L.
        • Lim K.N.
        • Juarbe H.M.
        Two cases of clinical and histologic hepatotoxicity associated with troglitazone.
        Ann Intern Med. 1998; 129: 36-38
        • Neuschwander-Tetri B.A.
        • Isley W.L.
        • Oki J.C.
        • et al.
        Troglitazone-induced hepatic failure leading to liver transplantation.
        Ann Intern Med. 1998; 129: 38-41
        • Vella A.
        • DeGroen P.C.
        • Dineen S.F.
        Fatal hepatotoxicity associated with troglitazone.
        Ann Intern Med. 1998; 129 ([letter]): 1080
        • Shibuya A.
        • Watanabe M.
        • Fujita Y.
        • et al.
        An autopsy case of troglitazone-induced fulminant hepatitis.
        Diabetes Care. 1998; 21: 2140-2143
        • Herrine S.K.
        • Choudhary C.
        Severe hepatotoxicity associated with troglitazone.
        Ann Intern Med. 1999; 130 ([letter]): 163-164
        • Kohlroser J.
        • Mathai J.
        • Reichheld J.
        • Banner B.F.
        • Bonkovsky H.L.
        Hepatotoxicity due to troglitazone.
        Am J Gastroenterol. 2000; 95: 272-276
        • Booth A.M.
        • Caldwell S.H.
        • Jezzoni J.C.
        Troglitazone-associated hepatic failure.
        Am J Gastroenterol. 2000; 95 ([letter]): 557-558
        • Fukano M.
        • Amano S.
        • Sato J.
        • et al.
        Subacute hepatic failure associated with a new antidiabetic agent, troglitazone.
        Hum Pathol. 2000; 31: 250-253
        • Murphy E.J.
        • Davern T.J.
        • Shakil A.O.
        • et al.
        Troglitazone-induced fulminant hepatic failure.
        Dig Dis Sci. 2000; 45: 549-553
        • Jagannath S.
        • Rai R.
        Rapid-onset subfulminant liver failure associated with troglitazone.
        Ann Intern Med. 2000; 132 ([letter]): 677
        • Li H.
        • Heller D.S.
        • Leevy C.B.
        • Zierer K.G.
        • Klein K.M.
        Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
        J Diabetes Complications. 2000; 14: 175-177
        • Mitchell P.
        Shock as troglitazone withdrawn in UK.
        Lancet. 1997; 350: 1685
        • Graham D.J.
        • Green L.
        (Accessed October 10, 2001)
        • Graham D.J.
        • Drinkard C.R.
        • Shatin D.
        • Tsong Y.
        • Burgess M.
        Liver enzyme monitoring in patients treated with troglitazone.
        JAMA. 2001; 286: 831-833
        • Stolberg S.G.
        Stricter rules are urged on use of a diabetic drug.
        New York Times. 1999; : A9
        • National Prescription Audit Plus®
        • U.S. Department of Health and Human Services. Rezulin to be withdrawn from the market. March 21, 2000 [U.S. Food and Drug Administration website]
        (Accessed October 10, 2001)
        • Meyboom R.H.B.
        • Egberts A.C.G.
        • Edwards R.I.
        • Hekster Y.A.
        • de Kining F.H.P.
        • Gribnau W.J.
        Principles of signal detection in pharmacovigilance.
        Drug Saf. 1997; 16: 355-365
        • Graham D.J.
        • Waller P.C.
        • Kurz X.
        A view from regulatory agencies.
        in: Strom B.L. Pharmacoepidemiology. 3rd ed. John Wiley & Sons, New York, NY2000: 109-124
        • Rogers A.S.
        • Israel E.
        • Smith C.R.
        Physician knowledge, attitudes and behavior related to reporting adverse drug events.
        Arch Intern Med. 1988; 148: 1589-1592
        • Scott H.D.
        • Rosenbaum S.E.
        • Waters W.J.
        • et al.
        Rhode Island physicians’ recognition and reporting of adverse drug reactions.
        R I Med J. 1987; 70: 311-316
        • Kessler D.
        JAMA. 1993; 269: 2765-2768
        • Warren J.L.
        • McBean A.M.
        • Hass S.L.
        • Babish J.D.
        Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries.
        Arch Intern Med. 1994; 154: 1482-1487
        • Faich G.A.
        Adverse reaction monitoring.
        N Engl J Med. 1986; 314: 1589-1592
        • for the Evidence-Based Medicine Working Group
        • United States General Accounting Office. Adverse drug events: the magnitude of health risk is uncertain because of limited incidence data. GAO/HEHS-00-21, January 2000:1-47
        (Accessed October 11, 2001)
        • Griffin J.P.
        • Weber J.C.P.
        Voluntary systems of adverse reaction reporting. Part II.
        Adv React Ac Pois Rev. 1986; 1: 23-55
        • Moride Y.
        • Harambaru F.
        • Requejo A.A.
        • Begaud B.
        Under-reporting of adverse drug reactions in general practice.
        Br J Clin Pharmacol. 1997; 43: 177-181
        • Alvarez-Requejo A.
        • Carvajal A.
        • Moride B.B.
        • Vega T.
        • Arias L.
        Under-reporting of adverse drug reactions. Estimate based on spontaneous reporting scheme and a sentinel system.
        Eur J Clin Pharmacol. 1998; 54: 483-488
        • La Grenade L.
        • Graham D.J.
        • Nourjah P.
        Underreporting of serious adverse drug reactions due to over-the-counter drugs.
        JAMA. 2002; 286 ([letter]): 3081
        • Leiper J.M.
        • Lawson D.H.
        Why do doctors not report adverse drug reactions?.
        Neth J Med. 1985; 28: 546-550
        • Lee W.H.
        Acute liver failure.
        N Engl J Med. 1993; 329: 1862-1872
        • Hoofnagle J.H.
        • Carithers R.L.
        • Shapiro C.
        • Ascher N.
        Fulminant hepatic failure.
        Hepatology. 1995; 21: 240-252
        • Williams R.
        Classification, etiology, and consideration of outcome in acute liver failure.
        Semin Liver Dis. 1996; 16: 343-348
        • Bernuau J.
        • Rueff B.
        • Benhamou J.P.
        Fulminant and subfulminant liver failure: definition and causes.
        Semin Liver Dis. 1986; 6: 97-106
      1. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol. 1990;28:317–322

        • CDC Diabetes Cost-Effectiveness Study Group
        Plymouth Meeting. IMS Health, Inc, PA2000
        • McQuay H.J.
        • Moore R.A.
        Using numerical results from systematic reviews in clinical practice.
        Ann Intern Med. 1997; 126: 712-720
        • McAlister F.A.
        • Straus S.E.
        • Guyatt G.H.
        • et al.
        Users’ guides to the medical literature, XX.
        JAMA. 2000; 283: 2829-2836
        • Everhart J.E.
        Digestive diseases and diabetes.
        in: Harris M.I. Cowie C.C. Stern M.P. Boyka E.J. Reiber G.E. Bennett P.H. Diabetes in America. 2nd ed. National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD1995: 457-484 (NIH Publication No. 95-1468)
        • Zimmerman H.J.
        Hepatotoxicity. 2nd ed. Lippincott Williams & Wilkins, Philadelphia, PA1999
        • Iwase M.
        • Yamaguchi M.
        • Yoshinari M.
        • et al.
        A Japanese case of liver dysfunction after 19 months of troglitazone treatment.
        Diabetes Care. 1999; 22 ([letter]): 1382-1384
        • Malik A.H.
        • Prasad P.
        • Saboorian M.H.
        • Thiele D.L.
        • Malet P.F.
        Hepatic injury due to troglitazone.
        Dig Dis Sci. 2000; 45: 210-214
        • Schiano T.S.
        • Dolehide K.
        • Hart J.
        • Baker A.L.
        Severe but reversible hepatitis induced by troglitazone.
        Dig Dis Sci. 2000; 45: 1039-1042
        • Caldwell S.H.
        • Hespenheide E.E.
        • VonBorstel R.W.
        Myositis, microvesicular hepatitis and progression to cirrhosis from troglitazone added to simvastatin.
        Dig Dis Sci. 2001; 46: 376-378
        • Menon K.V.N.
        • Angulo P.
        • Lindor K.D.
        Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
        Am J Gastroenterol. 2001; 96: 1631-1634
        • Graham D.J.
        • Green L.
        Final Report. Office of Postmarketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD2000
        • Graham D.J.
        • Drinkard C.R.
        • Shatin D.
        Incidence of acute liver failure and hospitalized liver injury in a cohort of patients treated with troglitazone.
        Am J Gastroenterol. 2003; 98: 175-179
        • CDC Diabetes Cost-Effectiveness Study Group
        The cost-effectiveness of screening for type 2 diabetes.
        JAMA. 1998; 280: 1757-1763
        • Kennedy D.L.
        • Goldman S.A.
        • Lillie R.B.
        Spontaneous reporting in the United States.
        in: Strom B.L. Pharmacoepidemiology. 3rd ed. John Wiley & Sons, New York, NY2000: 151-174
        • Graham D.J.
        • Ahmad S.R.
        • Piazza-Hepp T.
        Spontaneous reports in the US.
        in: Mann R. Andrews E. Pharmacovigilance. John Wiley & Sons, New York, NY2002: 219-227
        • Derby L.E.
        • Jick H.
        • Henry D.A.
        • Dean A.D.
        Cholestatic hepatitis associated with flucloxacillin.
        Med J Aust. 1993; 158: 596-600
        • Millard P.S.
        • Wilcosky T.C.
        • Reade-Christopher S.J.
        • Weber D.J.
        Isoniazid-related fatal hepatitis.
        West J Med. 1996; 164: 486-491
        • Kassahun K.
        • Pearson P.G.
        • Tang W.
        • et al.
        Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
        Chem Res Toxicol. 2001; 14: 62-70
        • Okura T.
        • Nakamura M.
        • Takata Y.
        • et al.
        Troglitazone induces apoptosis via p53 and Gadd45 pathway in vascular smooth muscle.
        Eur J Pharmacol. 2000; 407: 227-235
        • Toyoda Y.
        • Tsuchida A.
        • Iwami E.
        • et al.
        Toxic effect of troglitazone on cultured rat hepatocytes.
        Life Sci. 2001; 68: 1867-1876
        • Yamamoto Y.
        • Nakajima M.
        • Yamazaki H.
        • et al.
        Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
        Life Sci. 2001; 70: 471-482
        • Toyoda M.
        • Takagi H.
        • Horiguchi N.
        • et al.
        A ligand for peroxisome proliferator-activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells.
        Gut. 2002; 50: 563-567
        • Yamakawa-Karakida N.
        • Sugita K.
        • Inukai T.
        • et al.
        Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemic cells by down-regulating c-myc gene expression via blockade of Tcf-4 activity.
        Cell Death Differ. 2002; 9: 513-526